Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

Subjects

Subjects :

Oncology
EXPRESSION
PD-L1
medicine.medical_specialty
Lung Neoplasms
Durvalumab
Treatment outcome
CLINICAL BENEFIT
PROGRAMMED DEATH LIGAND-1
Antineoplastic Agents, Immunological
MAGNITUDE
Human use
Carcinoma, Non-Small-Cell Lung
Internal medicine
medicine
Drug approval
Humans
Lung cancer
Drug Approval
Expert Testimony
Neoplasm Staging
business.industry
Antibodies, Monoclonal
International Agencies
Hematology
medicine.disease
Stage III Non-Small Cell Lung Cancer
Treatment Outcome
Neoplasm staging
business
RADIOTHERAPY

Details

Language :

English

ISSN :

09237534

Volume :

30

Issue :

2

Database :

OpenAIRE

Journal :

Annals of Oncology

Accession number :

edsair.doi.dedup.....865e53fca13b5836883fb1f722438977

Full Text :

https://doi.org/10.1093/annonc/mdy553